Volume 5, Number 37
Monday, September 19, 2005



In this issue: (click heading to view article)
BMI and the Incidence of AMD
Interocular Axial Length Difference in Eyes with Pediatric Cataracts
The Dragged-Fovea Diplopia Syndrome
IOL Implantation After Atopic Cataract Surgery and Decreased Incidence of Postoperative Retinal Detachment
Thin Flap LASIK: Analysis of Contrast Sensitivity, Visual and Refractive Outcomes
Deep Sclerectomy vs. Punch Trabeculectomy: Effect of Low-Dosage Mitomycin C
Briefly











BMI and the Incidence of AMD

Age related macular degeneration (AMD) is the most frequent cause of blindness among the elderly. Several studies have suggested, but not proved, that obesity may be one of the risk factors of AMD. In this case-control study, Iranian investigators assessed the relation between body mass index (BMI) and the incidence of AMD.

The study included 50 patients with AMD and 80 other subjects who were adjusted for age, sex, cigarette smoking, blood pressure and diabetes. Data analysis was performed by SPSS V9.0 using Student's t and chi(2) tests.

Forty-two percent of the subjects in the case group and 35 percent of those in the control group were men. Mean age of subjects in the case and control groups was 69.9 years (62 to 77 years) and 64.08 years (56 to 71 years), respectively. Mean BMI measured 25.38 (range 21 to 29) and 30.24 (26 to 34) in the case and control groups, respectively. Twelve percent of subjects in the case group were obese, 42 percent were overweight and 14 percent were lean. A total of 22.5 percent of subjects in the control group were obese, 45 percent were overweight and 7.5 percent were lean.

Results showed no significant difference in BMI between the case and control groups. Recent studies indicate that obesity is a probable risk factor for progression of AMD, but there is no significant relation with the presence of AMD. With multifactorial analysis, the authors were unable to identify any significant relation between the presence of AMD and the studied risk factors.

SOURCE: Moeini HA, Masoudpour H, Ghanbari H. A study of the relation between body mass index and the incidence of age related macular degeneration. Br J Ophthalmol 2005;89(8):964-6.
Table of Contents










Interocular Axial Length Difference in Eyes with Pediatric Cataracts

Investigators at the Medical University of South Carolina sought to report interocular axial length difference (IALD) between the operated eye and fellow eye at the time of pediatric cataract surgery. They conducted a retrospective analysis of 171 cataractous (operated) eyes (mean patient age at surgery, 56.9 months; range, 0.2 to 230.0), using descriptive statistics, analysis of covariance, and regression analysis.

The mean IALD was 0.05 +/- 1.15 mm. If absolute values were used, mean IALD was 0.76 +/- 0.86. Nearly half of the subjects (48 percent) showed an IALD of 0.5 mm or greater; 41 patients (24 percent) had operated (cataractous) eyes that were 0.5 mm or more shorter than the fellow eye, and 41 patients (24 percent) had operated eyes that were 0.5 mm or more longer than the fellow eye. The mean IALD in unilateral and bilateral cases was 0.10 +/- 1.33 and -0.03 +/- 0.76, respectively. If absolute values were used, it was 0.98 +/- 0.90 and 0.40 +/- 0.65 in unilateral and bilateral cases, respectively. IALD was more predictable in unilateral than in bilateral cases. In unilateral cases, age at surgery and AL of the operated eye correlated with IALD. IALD did not correlate with gender, ethnicity or type of cataract in either unilateral or bilateral cases.

SOURCE: Lal G, Trivedi RH, Wilson ME. Interocular axial length difference in eyes with pediatric cataracts. J AAPOS 2005;9(4): 358-62.
Table of Contents











The Dragged-Fovea Diplopia Syndrome

Researchers at Johns Hopkins’ Wilmer Ophthalmological Institute conducted a study aimed at identifying the clinical characteristics of the dragged-fovea diplopia syndrome, introducing a simple diagnostic test that aids in the evaluation of such patients and providing a simple treatment option to improve the diplopia in some of these patients.

The retrospective, observational case series included 95 affected eyes in 83 consecutive patients seen between January 1, 1993, and August 9, 2004, who were diagnosed with the dragged-fovea diplopia syndrome at one institution. Researchers reviewed the records of 222 patients who had been seen in the Krieger Children's Eye Center at the Wilmer Institute since 1993 with a diagnosis of maculopathy, internal limiting membrane, or dragged fovea. They collected ocular findings and history for those patients who reported binocular diplopia that was not amenable to prism therapy and not secondary to acquired strabismus.

They recorded the presence of metamorphopsia on Amsler grid testing or other clinical evidence of macular wrinkling, response to prism trial, response to the small-field central fusion test (lights on-off test), and response to partial occlusion with Scotch Satin tape (3M Co., St. Paul, MN). The 69 patients who were tested with the lights on-off test responded positively, demonstrating rapid central fusion with room lights off, and recurrence of central diplopia with peripheral fusion with room lights on. Forty-six patients (of 64 tested) were receptive to monocular occlusion with Scotch Satin tape.

The authors of the study concluded that dragged-fovea diplopia syndrome consists of central diplopia in the presence of peripheral fusion, secondary to dragging of the fovea in one or both eyes by retinal disease. They maintain that central diplopia cannot be eliminated by prism therapy or eye muscle surgery. They also state that the lights on-off test has proved pathognomonic for this syndrome, and many patients have benefited from partial monocular occlusion with Scotch Satin tape.

SOURCE: De Pool ME, Campbell JP, Broome SO, Guyton DL. The dragged-fovea diplopia syndrome: clinical characteristics, diagnosis, and treatment. Ophthalmol 2005;112(8):1455-62.
Table of Contents











IOL Implantation After Atopic Cataract Surgery and Decreased Incidence of Postoperative Retinal Detachment

The rate of postoperative retinal detachment in eyes with intraocular lens (IOL) and no intraoperative posterior capsule rupture seems to be low, according to results of a study by Tokyo’s Keio University School of Medicine. The investigators believe that IOL implantation with capsular bag fixation may reduce the incidence of postoperative retinal detachment triggered by lens surgery for atopic cataract.

In a retrospective review, the investigators followed 169 eyes of 126 patients who underwent cataract surgery for atopic cataract for more than one year. None of the eyes previously had a retinal detachment or retinal detachment surgery. The eyes were divided into 132 eyes of 95 patients with an IOL implantation (IOL group) and 37 eyes of 31 patients without an IOL implantation (aphakia group). The postoperative visual acuity and incidence of postoperative retinal detachment were compared between the two groups. The effects of the location of the causative retinal breaks, intraoperative posterior capsule rupture, and postoperative posterior capsulotomy on the incidence of retinal detachments were evaluated.

Results showed that final visual acuity was better than or equal to 20/20 in 128 eyes (97.0 percent) of the IOL group and in 29 eyes (78.4 percent) of the aphakia group. Retinal detachment after an uncomplicated cataract surgery occurred in three eyes (2.3 percent) of the IOL group and in 8 eyes (25.8 percent) of the aphakia group. Two of three eyes (66.7 percent) in the IOL group and one of eight eyes (16.7 percent) in the aphakia group that later developed a retinal detachment had an intraoperative posterior capsule rupture. Posterior capsulotomy by YAG laser did not seem to alter the incidence of postoperative retinal detachment in either the IOL (2.0 percent) or the aphakia group (25.0 percent).

SOURCE: Inoue M, Shinoda K, Ishida S, et al. Intraocular lens implantation after atopic cataract surgery decreases incidence of postoperative retinal detachment. Ophthalmology 2005, Aug 9 [Epub ahead of print].
Table of Contents











Thin Flap LASIK: Analysis of Contrast Sensitivity, Visual and Refractive Outcomes

The purpose of this study by Spanish researchers was to analyze refractive, visual and contrast sensitivity outcomes of LASIK performed under thin flaps (less than 100 microns), and compare them with those of conventional thicker flaps.

In the retrospective study, 280 consecutive eyes that had LASIK for myopia using the Moria LSK-One microkeratome and the Technolas 217C excimer laser were included. Investigators compared efficacy, predictability and contrast sensitivity indicators among three groups of flap thicknesses: thin (less than 100 microns, 105 patients), medium (100 to 129 microns, 122 patients), and thick (greater than 130 microns, 53 patients).

Refractive results were excellent and comparable among the three groups; however, visual outcomes--measured as efficacy, postoperative evaluation of uncorrected visual acuity and contrast-sensitivity test--were significantly better in the thin flap group. Efficacy results were 92.9 percent, 91.0 percent, and 81.0 percent in the thin, medium and thick flap groups, respectively, and the rate of enhancements was 0 percent, 2.3 percent, and 5.6 percent, respectively. With contrast sensitivity changes between preoperative and postoperative values at month three of follow-up, the thin flap group achieved the preoperative levels at three spatial frequencies (3, 6, and 18 cycles per degree), while the thicker flap groups maintained lower than preoperative levels at more than two spatial frequencies. When comparing contrast sensitivity values among the three groups, the thin flap group also obtained the best results at lower spatial frequencies.

Investigators concluded that thin flap LASIK is a safe technique to correct myopic defects, since it blends the advantages of surface and lamellar procedures (minimal debilitation of corneal biomechanical architecture with the rapid and comfortable visual recovery of lamellar approaches). Moreover, it achieves excellent refractive outcomes, a lower rate of enhancements and a good visual performance with better contrast sensitivity test results.

SOURCE: Cobo-Soriano R, Calvo MA, Beltran J, et al. Thin flap laser in situ keratomileusis: Analysis of contrast sensitivity, visual, and refractive outcomes. J Cataract Refract Surg 2005;31(7):1357-65.
Table of Contents











Deep Sclerectomy vs. Punch Trabeculectomy: Effect of Low-Dosage Mitomycin C

Italian researchers conducted a prospective, randomized clinical trial aimed at comparing intraocular pressure (IOP) behavior after deep sclerectomy (DS) and trabeculectomy with the Crozafon-De Laage Punch (TP), using low-dosage intraoperative mitomycin C (MMC) in both techniques.

Forty patients who met inclusion and exclusion criteria were scheduled for glaucoma surgery. They were randomized to undergo either a nonpenetrating DS with MMC (DSMMC) (19 eyes) or a TP with MMC (TPMMC) (21 eyes). Postoperative examinations were performed at the first day; the first, second and third weeks; and the first, third, sixth, ninth and twelfth months. Postoperative complications, number of antiglaucoma medications and the IOP level were checked at each control. Complete success (without antiglaucoma medications) and qualified success (with or without medications) were assessed at two target IOP levels, namely 21 mmHG and lower, and 17 mmHg and lower in both groups. The success rates at the 21 mmHG and lower target IOP level were compared with those from previous series of patients who had undergone DS without MMC (historical control group).

Data from all eyes were available until the twelfth month. The mean preoperative IOP +/- SD was 29.6 +/- 5.8 mmHg in DSMMC eyes, 28.0 +/- 6.0 in TPMMC eyes; the mean IOP at the first postoperative day was 12.5 +/- 4.2 and 13.9 +/- 6.5 mmHg, while at the endpoint the mean IOP was 14.5 +/- 4.0 and 16.1 +/- 3.8, respectively, with significant reduction of the preoperative IOP in both groups. Complete success (21 mmHg or lower target IOP) in 15 eyes (78.9 percent) of the DSMMC group and in 15 eyes (71.4 percent) of the TPMMC group was respectively found, while qualified success was achieved in all the eyes. When a 17 mmHg or lower target IOP was considered, complete success in 12 eyes (63.1 percent) and 13 eyes (61.9 percent), and qualified success in 13 eyes (68.4 percent) and 15 eyes (71.4 percent) were found in the DSMMC and TPMMC groups, respectively. No significant intergroup differences were found in terms of success rate. There is no statistical significance in the Kaplan-Meier cumulative survival curves as for complete and qualified success rate in both surgical groups for a 17 mmHg or lower target IOP. Hypotony and shallow anterior chamber were significantly more frequent postoperative complications in TPMMC when compared with the DSMMC group. The historical comparison between the DSMMC group and simple DS cases shows no significant difference between the groups, with a mild positive trend in DSMMC when compared with DS eyes.

Both techniques, DSMMC and TPMMC, control IOP efficaciously at the endpoint set in the trial. The authors believe their results indicate that low-dosage MMC can be considered a mild enhancement of DS IOP-lowering effect without any negative effect on the well-known intra- and postoperative safety of the technique.

SOURCE: Cillino S, Di Pace F, Casuccio A, Lodato G. Deep sclerectomy versus punch trabeculectomy: effect of low-dosage mitomycin C. Ophthalmologica 2005;219(5):281-6.
Table of Contents





BRIEFLY
  • PHARMACEUTICAL COMPANY SIGNS AGREEMENT TO LICENSE NANOTECHNOLOGY TO DEVELOP ALLERGY PRODUCTS. Illinois-based BioSante Pharmaceuticals, Inc. announced that it has signed a Material Transfer and Option Agreement with an undisclosed European pharmaceutical company for an option to obtain an exclusive, worldwide license to use BioSante's calcium phosphate nanotechnology (CaP) to develop a series of allergy products. The partner company will fund its development of potential products for the treatment of conditions including rhinitis, asthma, conjunctivitis and dermatitis. Under the terms of the option agreement, BioSante will receive a $250,000 upfront option payment. If the option is exercised and the parties enter into an exclusive license agreement, BioSante will receive a one-time license fee, annual maintenance payments, milestone payments upon the achievement of regulatory milestones and royalties on commercial sales of any allergy product that is developed using CaP. For more information, go to www.biosantepharma.com.
  • TRANSPLANT REJECTION DRUG LOOKS PROMISING FOR TREATING INFLAMMATORY EYE DISEASE. Mycophenolate mofetil, an immunosuppresive drug used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases, according to researchers at Johns Hopkins. Investigators said that the drug seemed to be effective even in patients who had failed treatment from other immunosuppressants. Eighty-four patients received the drug, of whom 61 percent had uveitis, 17 percent had scleritis, 11 percent had mucous membrane pemphigoid and 11 percent had inflammation behind the eye or in other areas. Patients took two pills each morning and two each evening, for a total dose of 2 grams daily. Thirty-six patients (43 percent) already had been treated with at least one other immunosuppressive drug. The results of the study, published in the August 2005 issue of Ophthalmology, showed that 81 patients (97 percent) had control of their ocular inflammation after one month of treatment. Eighty-two percent of patients had control of their inflammation and were able to taper their dose of the steroid prednisone to 10 or fewer mg daily. Seven patients discontinued the drug because of adverse effects such as stomach upset or mild diarrhea. In most cases, said the chief investigator, lowering the dose of medication reduced side effects. The drug dosage can then be increased without the side effects returning.


Table of Contents




 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
It's only been up and running a few short weeks. Yet, it's already clear that the Check Yearly. See Clearly.(SM) marketing campaign is opening consumers' eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.